
Eli Lilly Plans to Seek Approval for Next-Generation Anti-Obesity Drug Retatrutide
Eli Lilly intends to file for regulatory approval of its investigational anti-obesity drug Retatrutide in early 2027 after successful late-stage trial results, targeting obesity and related conditions.












